Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

In this study, the 200mg dose of filgotinib was associated with a higher proportion achieving clinical remission at week 10 (induction phase; difference vs placebo of 10.8%-11.5%) and at week 58 (maintenance phase; difference of 26%; 95% CI 16.0–35.9; p<0.0001).

Source:

The Lancet